Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: Final results of EORTC randomized trial 30891 with 12 years of follow-up

European Urology

Volumn 66, Issue 5, 2014, Pages 829-838

  Studer, Urs E ^a   Whelan, Peter ^b   Wimpissinger, Florian ^c   Casselman, Jacques ^d   De Reijke, Theo M ^e   Knönagel, Hartmut ^f   Loidl, Wolfgang ^g   Isorna, Santiago ^h   Sundaram, Subramanian K ⁱ   Collette, Laurence ^j  

^a UNIVERSITY OF BERN   (Switzerland)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^d Algemeen Ziekenhuis Damiaan Oostende   (Belgium)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft   (Austria)

^h Hospital Nuestra Senora del Pino   (Spain)

ⁱ PINDERFIELDS GENERAL HOSPITAL   (United Kingdom)

^j EORTC DATA CENTER   (Belgium)

more..

Author keywords

Androgen deprivation; Deferred treatment; Prostate cancer; Surrogate; Survival

Indexed keywords

BUSERELIN; CYPROTERONE ACETATE; ANTIANDROGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARALYSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; URETER OBSTRUCTION; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASMS, HORMONE-DEPENDENT; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTOR; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922268118     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.07.024     Document Type: Article

References (29)

1. U.E. Studer, P. Whelan, W. Albrecht et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891 J Clin Oncol 24 2006 1868 1876
2. U.E. Studer, L. Collette, P. Whelan et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M2 prostate cancer not suitable for local curative treatment (EORTC 30891) Eur Urol 53 2008 941 949
3. I.M. Thompson, D.K. Pauler, P.J. Goodman et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter N Engl J Med 350 2004 2239 2246
4. G.L. Andriole, D.G. Bostwick, O.W. Brawley et al. Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
5. M. Wirth, C. Tyrrell, M. Wallace et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression Urology 58 2001 146 151
6. T.B. Dorff, T.W. Flaig, C.M. Tangen et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study J Clin Oncol 29 2011 2040 2045
7. TNM classifications. Geneva, Switzerland: Union International Contre le Cancer; 1978-82.
8. S.J. Pocock, R. Simon Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial Biometrics 31 1975 103 115
9. J.G. Klign, H.J. de Voogt, F.H. Schroeder, F.H. de Jong Combined treatment with buserelin and cyproterone in metastatic prostatic carcinoma Lancet 2 1985 493
10. I.M. Thompson, E.J. Zeidman, F.R. Rodriguez Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate J Urol 144 1990 1479 1480
11. J.D. Kalbfleisch, R.L. Prentice The statistical analysis of failure time data ed. 2 2002 John Wiley New York, NY
12. J.P. Fine, R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
13. F.H. Schröder, K.H. Kurth, S.D. Fossa et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846 - a phase III study J Urol 172 2004 923 927
14. M.P. Wirth, L. Weissbach, F.J. Marx et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer Eur Urol 45 2004 267 270
15. P. Iversen, D.G. McLeod, W.A. See et al. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide early prostate cancer programme at a median follow-up of 9.7 years BJU Int 105 2010 1074 1081
16. D. Kirk Immediate vs. deferred hormone treatment for prostate cancer: how safe is androgen deprivation? Medical Research Council Prostate Cancer Working Party Investigators Group BJU Int 86 Suppl 2000 220
17. M.V. Pilepich, R. Caplan, R.W. Byhardt et al. Phase III trial of androgen suppression using goserelin in unfavourable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31 J Clin Oncol 15 1997 1013 1021
18. M. Bolla, D. Gonzalez, P. Warde et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
19. M. Bolla, L. Collette, L. Blank et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial Lancet 360 2002 103 106
20. M.V. Pilepich, K. Winter, M.J. John et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
21. J. Laverdière, J.L. Gomez, L. Cusan et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer Int J Radiat Oncol Biol Phys 37 1997 245 246
22. J.Z. Wo, A.L. Zietman Why does androgen deprivation enhance the results of radiation therapy? Urol Oncol 26 2008 522 529
23. A.V. D'Amico, J. Manola, M. Loffredo, A.A. Renshaw, A. DellaCroce, P.W. Kantoff 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 2004 864 866
24. C.U. Jones, D. Hunt, D.G. McGowan et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
25. S. Kumar, M. Shelley, C. Harrison, B. Coles, T.J. Wilt, M.D. Mason Neo-adjuvant and adjuvant hormone therapy for localized and locally advanced prostate cancer Cochrane Database Syst Rev 2006 CD006019
26. C.A. Lawton, K. Winter, K. Murray et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 49 2001 937 946
27. M. Bolla, G. Van Tienhoven, P. Warde et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study Lancet Oncol 11 2010 1066 1073
28. M. Bolla, T.M. de Reijke, G. Van Tienhoven et al. Duration of androgen suppression in the treatment of prostate cancer N Engl J Med 360 2009 2516 2527
29. U.E. Studer, P.C. Albertsen It's time to change the treatment paradigm for prostate cancer! Eur Urol 63 2013 97 99